Assenagon Asset Management S.A. Sells 13,202 Shares of United Therapeutics Corporation $UTHR

Assenagon Asset Management S.A. cut its stake in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 38.8% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 20,804 shares of the biotechnology company’s stock after selling 13,202 shares during the period. Assenagon Asset Management S.A.’s holdings in United Therapeutics were worth $8,721,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of UTHR. F m Investments LLC increased its holdings in United Therapeutics by 1.3% during the 2nd quarter. F m Investments LLC now owns 2,580 shares of the biotechnology company’s stock worth $741,000 after acquiring an additional 33 shares during the period. HB Wealth Management LLC grew its position in shares of United Therapeutics by 2.9% during the 2nd quarter. HB Wealth Management LLC now owns 1,235 shares of the biotechnology company’s stock valued at $355,000 after purchasing an additional 35 shares in the last quarter. WealthCollab LLC increased its holdings in shares of United Therapeutics by 55.9% in the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock worth $30,000 after purchasing an additional 38 shares during the period. Park Avenue Securities LLC raised its position in shares of United Therapeutics by 1.7% in the second quarter. Park Avenue Securities LLC now owns 2,353 shares of the biotechnology company’s stock worth $676,000 after buying an additional 39 shares in the last quarter. Finally, First Financial Bankshares Inc raised its position in shares of United Therapeutics by 0.3% in the first quarter. First Financial Bankshares Inc now owns 13,769 shares of the biotechnology company’s stock worth $4,245,000 after buying an additional 42 shares in the last quarter. 94.08% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities analysts recently commented on the company. UBS Group boosted their target price on United Therapeutics from $580.00 to $600.00 and gave the stock a “buy” rating in a research report on Thursday, November 6th. Weiss Ratings reissued a “buy (b-)” rating on shares of United Therapeutics in a report on Monday, December 8th. Morgan Stanley set a $447.00 price objective on shares of United Therapeutics in a research report on Wednesday, October 29th. HC Wainwright lifted their target price on shares of United Therapeutics from $500.00 to $525.00 and gave the company a “buy” rating in a research report on Thursday, October 30th. Finally, Jefferies Financial Group reissued a “buy” rating and issued a $575.00 price target on shares of United Therapeutics in a research note on Wednesday, November 19th. Eight equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $505.00.

Insider Buying and Selling

In other United Therapeutics news, COO Michael Benkowitz sold 22,500 shares of the business’s stock in a transaction on Monday, October 6th. The shares were sold at an average price of $450.24, for a total value of $10,130,400.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In the last 90 days, insiders have sold 625,164 shares of company stock valued at $284,916,107. 10.30% of the stock is owned by company insiders.

Key Headlines Impacting United Therapeutics

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: Director Tommy G. Thompson sold 910 shares but still holds 8,480 shares (~$4.25M), signaling continued insider alignment with shareholders. SEC Filing — Thompson Sale
• Neutral Sentiment: All transactions were disclosed via SEC filings and covered by financial sites, providing transparency; investors should check the filings for whether sales were part of pre-set programs (e.g., 10b5-1) that reduce interpretive weight. SEC Filings
• Negative Sentiment: CEO Martine A. Rothblatt sold a total of 6,000 shares across Dec. 17 and Dec. 19 at ~ $501–$507, leaving her with only 130 shares — a ~94%+ reduction in reported ownership; that sharp drop can be read as a meaningful negative signal to some investors. SEC Filing — Rothblatt Sales
• Negative Sentiment: Additional senior insider sales: CFO and COO transactions reported (CFO ~$1.74M; COO ~$11.17M), increasing the volume and scope of executive selling within days — a likely near-term headwind for sentiment absent an explanatory disclosure. ABN: CEO Sale Coverage ABN: CFO Sale Coverage ABN: COO Sale Coverage

United Therapeutics Price Performance

Shares of UTHR opened at $517.13 on Friday. United Therapeutics Corporation has a 1 year low of $266.98 and a 1 year high of $518.61. The stock has a 50 day simple moving average of $463.63 and a two-hundred day simple moving average of $380.95. The firm has a market cap of $22.27 billion, a P/E ratio of 19.60, a P/E/G ratio of 5.13 and a beta of 0.86.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings results on Wednesday, October 29th. The biotechnology company reported $7.16 EPS for the quarter, topping the consensus estimate of $6.89 by $0.27. The firm had revenue of $799.50 million for the quarter, compared to the consensus estimate of $812.87 million. United Therapeutics had a net margin of 40.65% and a return on equity of 18.83%. The business’s revenue was up 6.8% compared to the same quarter last year. During the same period last year, the firm posted $6.39 earnings per share. On average, equities analysts anticipate that United Therapeutics Corporation will post 24.48 earnings per share for the current year.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.